Anti-Rheumatic Rx
Catherine Sims, MD DrCassySims
2 years 9 months ago
How to prescribe methotrexate in a post-Roe era:
Abstract #L09
💊 6% of > 1,700 patients reported access issues to MTX
-63% had a delay in filling script
🤰Excessive questions about possibility of pregnancy
🧑⚕️Pharmacy refused to fill
#ACR22 #ACRbest @RheumNow
Richard Conway RichardPAConway
2 years 9 months ago
Broder et al. HCQ alone vs steroid alone as maintenance in ESKD due to SLE. HCQ less cardiac events, less infection. @RheumNow #ACR22 Abstr#0539 https://t.co/mb3Eof2Uiv https://t.co/3i3ZTY25ru
The ability to prevent RA in individuals at risk is a holy grail in rheumatology. There is a long history dating back to the PROMPT trial of methotrexate and PRAIRIE trial of rituximab. Both otrials showed an effect, but it seemed more likely to be a delaying of RA than prevention or modulation. Framing it another way, there were better outcomes in pre-RA because we were actually treating RA as it emerged with a proven effective treatment. It is
sheila RHEUMarampa
2 years 9 months ago
HCQ tx thresholds study by Prof Garg:
🔸HCQ >=500ng/ml: good threshold to detect adherence
🔸HCQ 750-1000ng/ml: effective thresholds to prevent flares
🔸CKD>=2: 4x ⬆️odds of HCQ>1500ng/ml (supraTx! dose adj.)
Interesting data.
Game changing?🧐
#ACR22 @RheumNow ABST#0344 #ACRBest https://t.co/GxlucrTeE5
The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).
Dr. Antoni Chan synovialjoints
2 years 9 months ago
Adding MTX to Pegloticase for 52 wks in gout
◦ Improved response rate by 30%
◦ Reduced discontinuation rate by 40%
◦ Greater resolution of tophi by 20%
◦ Similar safety profile in MTX vs non-MTX groups
Botson J, MIRROR RCT https://t.co/ifXLdvOv0K #ACR22 #ACRBest @RheumNow https://t.co/le9ggUa2Xk
Robert B Chao, MD doctorRBC
2 years 9 months ago
NSAIDs plus TNFi (celecoxib and golimumab) therapy in ankylosing spondylitis did not show significant decrease in radiographic progression compared to TNFi monotherapy.
*Numerical reduction in syndesmophytes 11% vs. 25%
Abs#0546
@RheumNow #ACR22
#ACRBest https://t.co/pG5F3xdsh9
Richard Conway RichardPAConway
2 years 9 months ago
Khanna @sclerodermaUM. SLS-III MMF+Pirfenidone vs MMF alone in SSc-ILD. Underpowered due to COVID (51 vs 150). No difference FVC 18 months ?more rapid improvement in combo. Better HRCT, PROs in combination. Need another study! @RheumNow #ACR22 Abstr#0520 https://t.co/K2Ne6PSHkS https://t.co/P6A7OJpzCf
Janet Pope Janetbirdope
2 years 9 months ago
#ClinicalPearl #Methotrexate is recommended for Rx in all EXCEPT…#ACR22 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 9 months ago
#ACR22 Plenary 1. Abstr#0001 Another important use of #methotrexate. MIRROR RCT showed greater response in pegloticase + MTX vs pegloticase + PBO and lower infusion reaction. Be interesting to define MTX dose and ?other DMARDs esp in patients with CKD @RheumNow #ACRBest https://t.co/xkP6ZZGQfu
Bella Mehta bella_mehta
2 years 9 months ago
Abst#0001 MIRROR RCT at #ACR22 #plenary
Pts with gout on #pegloticase and #gout
sustained higher urate lowering response in pts cotreated with #MTX
benefit beyond 6 months
@rheumnow https://t.co/rTZ3fPaFJS
Robert B Chao, MD doctorRBC
2 years 9 months ago
Excellent start to the first plenary session!
MIRROR study - MTX coadministration with pegloticase for gout treatment
- doubling of efficacy and 7x decrease in infusion reactions
- less anti-PEG abs
@RheumNow #ACR22 Abs#0001 https://t.co/V1HIYypmpO
Poster Hall